Abstract
In high-grade AOC patients, the combination of immunotherapy, PARP inhibitors (PARPi), and antiangiogenic agents, may enhance the efficacy of each treatment. Different chemotherapy-free combinations were previously found to be feasible. A significant activity of the Durva + Ola +/- Bev combination was reported in platinum-sensitive recurrent (PSR) AOC in the MEDIOLA trial. However the efficacy of the triplet in platinum resistant relapse (PRR) has never been assessed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
